^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DO-1

    i
    Other names: DO-1, OMO-1, OMO1, OMO 1, JNJ-38877618
    Company:
    Allist, DeuterOncology, Octimet
    Drug class:
    c-MET inhibitor, SLC22A2 inhibitor
    Related drugs:
    12ms
    A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer. (PubMed, Oncologist)
    OMO-1 was tolerated at the dose of 250 mg BID and shows initial signs of MET inhibition and anti-tumor activity in METex14 mutated NSCLC patients.
    Clinical • P1 data • Journal • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation
    |
    DO-1
    3years
    OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer. (PubMed, NPJ Breast Cancer)
    Corroborating this finding, cisplatin delivery to the 4T1 primary tumor was enhanced upon OMO-1 treatment, increasing cisplatin DNA-adduct levels and tumor cell death. Although verification in additional cell lines is warranted, our findings provide initial evidence that TNBC patients may benefit from OMO-1 treatment, even in cases of non-c-MET addicted tumors.
    Preclinical • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    cisplatin • DO-1